CRP and type 2 diabetes mellitus: However, a 6-week study of empagliflozin (25 mgday) in 58 subjects with T2DM showed no difference compared to placebo [239], and the post hoc analysis of the Empagliflozin in Heart Failure Patients with Reduced Ejection Fraction (Empire HF) trial that found no change in CRP [240].